keyword
respiratori
virus
laboratori
diagnosi
molecular
method
polymeras
chain
reaction
molecular
test
detect
respiratori
virus
sensit
detect
virus
tradit
method
cultur
antigen
detect
sever
molecular
assay
avail
clear
food
drug
administr
differ
respect
virus
detect
instrument
throughput
handson
time
need
separ
nucleic
acid
extract
sensit
certain
group
virus
issu
associ
molecular
test
respiratori
virus
includ
possibl
falseneg
result
due
sequenc
variant
inabl
mani
assay
discrimin
rhinovirus
enterovirus
abil
detect
viral
nucleic
acid
asymptomat
individu
increas
preval
coinfect
purpos
review
provid
updat
recent
advanc
molecular
test
respiratori
virus
focus
primarili
commerci
avail
assay
clear
food
drug
administr
fda
use
unit
state
rather
detail
look
technic
aspect
assay
attent
paid
herein
practic
aspect
test
virus
detect
nucleic
acid
extract
requir
throughput
forth
refer
provid
detail
descript
sensit
specif
well
technic
aspect
issu
pertin
clinician
laboratorian
regard
molecular
assay
gener
respiratori
viru
detect
also
discuss
purpos
articl
follow
virus
consid
agent
viral
respiratori
tract
infect
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
rhinovirus
human
coronavirus
human
metapneumoviru
adenovirus
although
virus
human
bocaviru
wu
ki
polyomavirus
may
detect
human
respiratori
tract
specimen
role
caus
respiratori
tract
diseas
firmli
establish
therefor
cover
respiratori
tract
diseas
caus
infect
virus
impos
signific
burden
human
societi
communitybas
studi
reveal
high
preval
viral
respiratori
infect
young
children
experienc
greatest
number
infect
annual
number
infect
decreas
age
studi
also
note
rhinovirus
influenza
virus
coronavirus
tend
caus
highest
number
infect
viral
respiratori
tract
infect
also
import
caus
morbid
mortal
adult
elderli
particularli
risk
addit
young
elderli
group
underli
condit
solidorgan
hematopoiet
stemcel
transplant
recipi
patient
chronic
obstruct
pulmonari
diseas
asthma
also
known
higher
risk
sever
complic
viral
respiratori
tract
infect
exampl
import
viral
respiratori
infect
rel
small
countri
netherland
countrywid
studi
led
estim
individu
visit
physician
annual
acut
respiratori
tract
infect
oblig
intracellular
pathogen
abil
provid
use
laboratori
diagnosi
virus
histor
lag
behind
bacteri
infect
introduct
molecular
method
diagnost
virolog
laboratori
tradit
method
cell
cultur
antigen
detect
predomin
method
detect
respiratori
virus
clinic
specimen
convent
cellcultur
detect
respiratori
virus
involv
select
rang
cell
type
known
support
growth
respiratori
virus
observ
cell
microscopi
look
morpholog
chang
refer
cytopath
effect
characterist
differ
virus
major
drawback
convent
viral
cultur
take
long
week
result
serious
compromis
clinic
use
method
although
variat
convent
cell
cultur
develop
shorten
time
detect
still
sever
respiratori
virus
grow
poorli
cultur
also
limit
use
method
develop
antigendetect
method
consid
major
advanc
laboratori
diagnosi
viral
respiratori
infect
detect
viral
antigen
directli
patient
specimen
either
fluoresc
antibodi
method
enzym
immunoassaybas
techniqu
possibl
obtain
result
within
clinic
use
time
period
antigendetect
test
remain
import
tool
viral
diagnost
howev
method
also
shortcom
method
poor
sensit
viral
target
particularli
adult
popul
addit
owe
lack
conserv
antigen
sever
respiratori
virus
rhinovirus
coronavirus
antigendetect
assay
exist
molecular
detect
viral
nucleic
acid
revolution
laboratori
diagnosi
viral
infect
develop
nucleic
acid
amplif
technolog
attempt
detect
viral
nucleic
acid
clinic
specimen
method
dotblot
hybrid
larg
unsuccess
lack
sensit
public
first
descript
nucleic
acid
amplif
method
polymeras
chain
reaction
pcr
describ
nucleic
acid
could
specif
exponenti
amplifi
readili
detect
level
soon
follow
numer
public
describ
success
applic
method
detect
viral
nucleic
acid
clinic
specimen
today
pcr
nucleic
acid
amplif
test
naat
begin
supplant
tradit
laboratori
method
point
futur
method
like
primari
laboratori
method
viral
diagnost
advantag
disadvantag
associ
use
naat
diagnosi
viral
respiratori
infect
box
advantag
includ
extrem
sensit
techniqu
fact
viral
viabil
maintain
prior
test
allow
potenti
ship
specimen
long
distanc
test
laboratori
contrast
problem
associ
ship
specimen
cultur
especi
virus
rsv
known
rapidli
lose
viabil
anoth
advantag
abil
detect
virus
human
coronavirus
practic
cultur
antigendetect
method
exist
rapid
sensit
specif
result
afford
molecular
test
also
allow
time
institut
antivir
therapi
proper
cohort
patient
admit
hospit
howev
disadvantag
associ
naat
test
well
exampl
potenti
appear
sequenc
variant
produc
falseneg
result
also
becom
well
establish
molecular
test
detect
viral
nucleic
acid
respiratori
specimen
obtain
asymptomat
individu
complic
interpret
result
naat
assay
also
expens
nonmolecular
method
although
introduct
ever
assay
market
expect
price
drop
molecular
test
issu
discuss
greater
depth
later
naat
detect
respiratori
virus
evolv
userdevelop
laboratorydevelop
test
use
convent
pcr
technolog
electrophoresisgel
detect
product
userdevelop
realtim
pcrbase
test
wherebi
amplifi
product
detect
technolog
primarili
involv
product
luminesc
signal
proport
amount
target
amplifi
problem
technolog
limit
respect
number
target
practic
amplifi
detect
multiplex
singl
reaction
mani
tradit
realtim
platform
target
maximum
real
drawback
one
want
comprehens
detect
differ
target
abil
identifi
virus
detect
convent
cultur
antigen
detect
method
rapid
accuraci
result
allow
time
institut
antivir
therapi
appropri
infect
control
viral
viabil
need
maintain
specimen
transport
condit
relax
allow
specimen
sent
distant
test
site
falseneg
result
due
exist
sequenc
variant
naat
often
result
detect
virus
asymptomat
individu
method
higher
cost
technolog
appear
commerci
format
abl
surmount
limit
platform
detail
descript
technolog
reader
refer
excel
review
deal
topic
extens
literatur
describ
noncommerci
userdevelop
naat
detect
respiratori
virus
review
deal
commerci
avail
assay
detect
respiratori
virus
reader
refer
review
deal
topic
howev
brief
observ
made
concern
assay
mani
exampl
literatur
comparison
molecular
assay
particular
viru
convent
method
cultur
andor
antigen
detect
virus
rsv
influenza
virus
appear
modest
real
increas
sensit
wherea
other
human
metapneumoviru
hmpv
human
rhinovirus
signific
increas
detect
molecular
method
addit
userdevelop
assay
tend
develop
detect
one
viru
one
group
relat
virus
constrain
previous
mention
limit
convent
realtim
assay
maximum
target
sign
symptom
respiratori
viru
infect
overlap
differ
virus
confid
rule
potenti
virus
would
necessari
run
batteri
assay
one
instanc
singl
direct
assay
may
use
geograph
area
annual
epidem
influenza
rsv
epidem
may
make
sens
test
virus
test
agent
compani
start
prodess
later
acquir
genprob
holog
holog
genprob
inc
san
diego
ca
offer
assay
molecular
detect
respiratori
virus
box
assay
base
taqman
realtim
pcr
technolog
requir
nucleic
acid
extract
either
roch
magna
pure
roch
diagnost
indianapoli
biomerieux
easymag
biomerieux
inc
durham
nc
autom
extractor
requir
reaction
run
cepheid
smartcycl
cepheid
sunnyval
ca
kit
contain
reagent
necessari
run
reaction
includ
intern
control
benefit
clear
vitro
diagnost
use
fda
public
describ
use
assay
compar
test
favor
result
comparison
influenza
pcr
assay
fail
detect
season
influenza
virus
sensit
similar
number
influenza
influenza
b
specimen
addit
compani
web
site
provid
perform
data
link
data
present
poster
present
assay
might
particularli
use
wish
screen
yearli
epidem
influenza
rsv
determin
caus
rsvlike
ill
young
children
test
neg
rsv
hmpv
parainfluenza
viru
might
consider
assay
subtyp
influenza
could
use
guid
antivir
therapi
drawback
assay
includ
necess
run
separ
assay
rule
target
fact
detect
parainfluenza
type
coronavirus
addit
requir
use
cepheid
smartcycl
would
limit
throughput
sampl
per
smartcycl
modul
quidel
corp
san
diego
ca
market
fdaclear
assay
detect
respiratori
virus
influenza
assay
detect
influenza
b
virus
hmpv
assay
detect
human
metapneumoviru
assay
sold
kit
format
contain
primer
fluoresc
label
probe
master
mix
intern
process
control
quidel
recommend
inclus
posit
control
assay
either
form
commerci
product
sell
separ
use
known
previous
posit
specimen
assay
approv
nasal
nasopharyng
swab
specimen
extract
biomerieux
nuclisen
easymag
autom
extractor
requir
amplif
either
cepheid
smartcycl
abi
fast
dx
influenza
assay
abi
fast
dx
hmpv
test
date
peerreview
evalu
quidel
assay
avail
perform
data
avail
download
compani
web
site
advantag
assay
includ
molecular
detect
import
common
respiratori
virus
c
kit
storag
temperatur
need
store
frozen
room
temperatur
setup
shelflif
reagent
disadvantag
includ
inabl
detect
respiratori
virus
lack
peerreview
evalu
assay
cepheid
genexpert
flu
assay
cepheid
sunnyval
ca
consist
singleus
dispos
cartridg
associ
instrument
includ
comput
analysi
softwar
fig
follow
addit
specimen
placement
instrument
extract
nucleic
acid
pcr
take
place
within
cartridg
independ
evalu
xpert
flu
test
report
assay
minut
handson
time
run
complet
minut
assay
detect
differenti
influenza
b
identifi
influenza
present
includ
intern
control
assay
fdaclear
use
nasal
aspir
wash
well
nasopharyng
swab
instrument
come
differ
iter
capabl
accommod
cartridg
time
addit
influenza
assay
cepheid
offer
sever
cartridg
detect
target
cepheid
genexpert
system
first
technolog
allow
democrat
molecular
test
molecular
test
first
introduc
diagnost
virolog
laboratori
view
technic
demand
method
requir
molecular
detect
respiratori
virus
highli
train
technologist
specimen
answer
format
genexpert
system
allow
molecular
test
laboratori
littl
previou
experi
area
clinic
laboratori
improv
amend
classifi
xpert
flu
assay
moder
complex
facilit
test
outbreak
influenza
initi
version
xpert
flu
assay
detect
influenza
differenti
influenza
grant
emerg
use
author
decemb
publish
comparison
version
xpert
flu
assay
convent
method
laboratorydevelop
techniqu
commerci
pcr
assay
detect
influenza
virus
reveal
accept
sensit
specif
somewhat
reduc
sensit
detect
virus
evalu
use
collect
retrospect
test
respiratori
specimen
subsequ
fdaclear
version
xpert
flu
assay
ad
abil
detect
influenza
b
report
sensit
detect
season
influenza
virus
influenza
b
virus
sensit
compar
laboratorydevelop
pcr
test
upfront
autom
nucleic
acid
extract
despit
reduc
sensit
virus
investig
indic
rapid
turnaround
time
xpert
flu
assay
make
reason
option
laboratori
test
two
peerreview
studi
compar
fdaclear
version
xpert
flu
assay
cultur
direct
fluoresc
antibodi
stain
antigen
immunoassay
refer
molecular
test
report
gener
enhanc
sensit
rel
convent
method
accept
perform
rel
refer
molecular
method
studi
support
use
xpert
flu
assay
rapid
diagnosi
influenza
cepheid
xpert
flu
assay
offer
laboratori
advantag
rapid
sensit
molecular
test
influenza
simpl
perform
dispos
selfcontain
cartridg
system
addit
abrog
need
upfront
nucleic
acid
extract
also
greatli
reduc
opportun
fals
posit
attribut
amplicon
contamin
affect
naat
disadvantag
assay
includ
depend
instrument
configur
limit
throughput
fact
assay
detect
influenza
virus
iquum
marlborough
offer
molecular
assay
call
liat
influenza
ab
assay
assay
fdaclear
nasopharyng
swab
detect
differenti
influenza
b
assay
sampleinanswerout
format
turnaround
time
minut
minut
handson
time
accord
inform
provid
compani
assay
consist
singleus
dispos
liat
influenza
ab
assay
tube
contain
test
reagent
associ
instrument
call
liat
analyz
assay
use
taqman
probe
realtim
pcr
chemistri
includ
appropri
control
simplic
oper
rapid
result
assay
consid
possibl
use
pointofcar
test
perform
data
provid
manufactur
indic
sensit
specif
rel
cultur
influenza
influenza
b
time
write
peerreview
evalu
assay
avail
focu
diagnost
inc
cypress
ca
market
fdaclear
molecular
diagnost
assay
detect
influenza
virus
rsv
simplexa
influenza
assay
detect
influenza
virus
differenti
influenza
simplexa
flu
ab
rsv
assay
detect
differenti
influenza
b
virus
rsv
assay
requir
use
integr
cycler
associ
comput
analysi
softwar
fig
assay
realtim
pcr
assay
use
bifunct
fluoresc
probeprim
combin
revers
primer
specif
amplifi
detect
viral
sequenc
includ
intern
control
assay
requir
regard
accept
specimen
type
nucleic
acid
extract
method
box
integr
cycler
use
novel
singleus
univers
disk
contain
reaction
posit
note
focu
market
molecular
assay
use
reaction
condit
differ
assay
simultan
run
disk
singl
independ
evalu
simplexa
flu
ab
rsv
avail
time
report
test
requir
minut
handson
time
result
avail
approxim
hour
investig
report
comparison
anoth
fdaclear
naat
nanospher
verigen
use
retrospect
prospect
specimen
simplexa
assay
lower
sensit
target
statist
signific
influenza
b
result
note
odd
manufactur
sensit
molecular
detect
respiratori
virus
data
investig
indic
strain
differ
could
explan
observ
manufactur
perform
data
avail
download
compani
web
site
focu
diagnost
also
offer
simplexa
flu
ab
rsv
direct
assay
use
direct
amplif
disk
disk
sampl
posit
extract
nucleic
acid
amplifi
viral
sequenc
influenza
b
rsv
use
adhes
foil
cover
reaction
posit
necessari
choos
run
specimen
wast
unus
posit
rather
disk
reus
specimen
run
assay
use
method
simplexa
assay
requir
integr
cycler
time
write
independ
evalu
assay
manufactur
data
avail
download
web
site
simplexa
assay
offer
advantag
multiplex
assay
preval
respiratori
virus
high
throughput
use
disk
cycl
program
allow
simultan
run
focu
diagnost
assay
simplexa
direct
assay
repres
anoth
choic
laboratori
consid
sampleinanswerout
platform
disadvantag
includ
assay
test
influenza
rsv
minim
peerreview
data
avail
addit
infecti
diseas
genet
target
nanospher
inc
northbrook
il
offer
commerci
fdaclear
assay
call
verigen
detect
influenza
rsv
nasopharyng
swab
specimen
assay
detect
differenti
influenza
b
rsv
also
provid
influenza
subtyp
inform
season
addit
assay
subtyp
rsv
version
product
avail
outsid
unit
state
includ
detect
mutat
confer
oseltamivir
resist
influenza
virus
assay
sampleinanswerout
format
therefor
requir
nucleic
acid
extract
includ
necessari
reagent
includ
process
inhibit
control
assay
use
novel
detect
technolog
take
place
singleus
cartridg
place
verigen
processor
sp
instrument
nucleic
acid
extract
purifi
targetamplifi
present
fig
hybrid
step
involv
gold
nanoparticl
bound
probe
specif
amplifi
product
use
part
detect
process
cartridg
place
verigen
reader
read
result
detect
light
scatter
rather
method
fluoresc
interest
thaxton
colleagu
publish
detail
descript
technolog
independ
evalu
report
assay
requir
minut
handson
time
result
readi
hour
singl
peerreview
evalu
verigen
assay
sensit
influenza
sensit
influenza
b
sensit
rsv
good
specif
target
determin
use
set
sever
hundr
retrospect
prospect
specimen
test
commerci
assay
discrep
result
resolv
use
laboratorydevelop
naat
advantag
verigen
includ
offer
anoth
choic
sampleinanswerout
format
limit
labor
time
well
reduc
risk
contamin
previous
mention
selfcontain
dispos
system
abil
detect
common
epidem
respiratori
virus
abil
subtyp
influenza
virus
asset
disadvantag
includ
low
throughput
although
increas
processor
modul
fact
influenza
rsv
detect
assay
genmark
esensor
respiratori
viral
panel
genmark
diagnost
carlsbad
ca
multiplex
pcr
assay
clear
fda
nasopharyng
swab
detect
respiratori
virus
influenza
season
influenza
b
rsv
b
parainfluenza
human
metapneumoviru
rhinoviru
adenoviru
c
kit
provid
reagent
perform
assay
requir
nucleic
acid
extract
biomerieux
nuclisen
easymag
follow
amplif
thermocycl
use
tube
follow
amplif
potenti
amplicon
load
esensor
cartridg
place
instrument
detect
take
place
novel
technolog
involv
product
electr
current
specif
bind
amplicon
goldplat
electrod
fig
instrument
random
access
space
cartridg
integr
comput
analysi
softwar
independ
evalu
found
assay
requir
hour
test
specimen
handson
time
hour
singl
peerreview
studi
evalu
esensor
test
frozen
specimen
pediatr
patient
compar
result
panel
laboratorydevelop
pcr
assay
overal
agreement
method
report
note
investig
report
genmark
assay
sensit
specif
laboratori
assay
detect
rhinovirus
although
found
assay
may
higher
sensit
adenoviru
type
assay
show
crossreact
adenovirus
found
speci
b
c
e
advantag
esensor
respiratori
viral
panel
includ
abil
detect
wide
rang
respiratori
virus
singl
assay
abil
subtyp
influenza
rsv
virus
potenti
higher
sensit
adenoviru
type
higher
specif
rhinovirus
potenti
disadvantag
assay
includ
inabl
detect
coronavirus
parainfluenza
type
requir
upfront
nucleic
acid
extract
potenti
contamin
issu
rais
need
manipul
pcr
product
follow
amplif
luminex
austin
tx
offer
multiplex
molecular
assay
detect
respiratori
virus
xtag
respiratori
viru
panel
rvp
xtag
rvp
fast
assay
assay
detect
differ
number
respiratori
virus
clear
specif
nucleic
acid
extract
method
box
version
assay
detect
differ
target
avail
global
market
outsid
unit
state
assay
use
multiplex
realtim
pcr
perform
thermocycl
use
reaction
tube
includ
extract
assay
control
overcom
technic
issu
associ
detect
product
larg
multiplex
pcr
assay
assay
use
proprietari
univers
tag
sort
system
wherebi
virusspecif
oligonucleotid
tag
ad
viral
amplicon
tag
amplicon
hybrid
liquid
suspens
microspher
bead
set
plate
bead
set
virusspecif
antitag
bound
surfac
bead
set
uniqu
identifi
ratio
dye
impregn
bead
color
bead
set
thu
repres
specif
viru
beadantitagtagamplicon
interact
follow
hybrid
bead
read
luminex
instrument
fig
flow
cell
use
dual
laser
one
identifi
bead
set
determin
whether
amplicon
bound
bead
emiss
phycoerythrin
report
run
time
rvp
assay
hour
includ
extract
rvp
fast
assay
decreas
run
time
elimin
assay
step
independ
assess
report
handson
time
fast
assay
min
time
result
includ
extract
requir
hour
wish
inform
detail
descript
rvp
technolog
publish
compani
xtag
rvp
assay
first
larg
multiplex
respiratori
viru
assay
enter
market
fdaclear
assay
sever
report
demonstr
increas
compar
sensit
detect
respiratori
virus
rel
antigen
detectioncultur
method
molecular
method
studi
demonstr
cost
save
realiz
implement
rvp
assay
place
convent
method
although
rvp
assay
increas
sensit
rel
convent
method
compar
multiplex
molecular
assay
rvp
assay
demonstr
reduc
sensit
target
parainfluenza
virus
rsv
likewis
rvp
fast
assay
although
demonstr
increas
sensit
rel
antigen
detectioncultur
method
report
reduc
sensit
target
rel
molecular
assay
gharabaghi
colleagu
report
reduc
sensit
influenza
b
adenovirus
anoth
studi
also
report
lower
sensit
adenovirus
recent
studi
note
lower
sensit
influenza
b
rsv
comparison
biofir
filmarray
advantag
xtag
rvp
assay
includ
abil
detect
wide
array
virus
singl
assay
high
throughput
increas
sensit
rel
tradit
method
potenti
cost
save
disadvantag
includ
inabl
detect
virus
coronavirus
rel
larg
amount
handson
time
report
reduc
sensit
target
rel
assay
need
multipl
user
intervent
includ
open
tube
contain
amplicon
increas
potenti
contamin
occur
xtag
rvp
fast
obviou
advantag
requir
less
handson
time
disadvantag
current
fdaclear
version
fewer
viral
target
biofir
formerli
idaho
technolog
filmarray
respiratori
panel
rp
biofir
diagnost
salt
lake
citi
ut
multiplex
realtim
pcr
assay
capabl
detect
viral
respiratori
agent
includ
adenoviru
coronavirus
metapneumoviru
influenza
parainfluenza
virus
rsv
rhinovirusenteroviru
note
assay
also
detect
bacteri
agent
bordetella
pertussi
mycoplasma
pneumonia
chlamydophila
pneumonia
assay
also
includ
rna
dna
control
must
posit
assay
produc
result
filmarray
rp
sampleinanswerout
test
use
singleus
dispos
pouch
contain
lyophil
reagent
associ
instrument
comput
clear
fda
nasopharyng
swab
fig
specimen
introduc
pouch
nucleic
acid
extract
follow
revers
transcript
nest
pcr
reaction
final
pcr
reaction
take
place
multiwel
array
product
detect
meltcurv
analysi
associ
instrument
room
singl
pouch
time
interest
detail
descript
filmarray
technolog
publish
manufactur
note
rp
assay
reliabl
discrimin
rhinovirus
enterovirus
coronaviru
compon
may
crossreact
strain
coronaviru
assay
reduc
sensit
adenoviru
speci
c
serotyp
updat
version
assay
increas
sensit
detect
adenoviru
c
serotyp
due
biofir
person
commun
sever
studi
demonstr
filmarray
rp
greater
sensit
antigen
detectioncultur
method
andor
sensit
gener
compar
molecular
method
confirm
manufactur
inform
studi
note
decreas
sensit
filmarray
fp
adenovirus
pierc
colleagu
also
report
use
collect
previous
character
adenoviru
type
addit
type
filmarray
rp
also
reduc
sensit
detect
adenoviru
type
although
investig
note
type
consid
import
caus
respiratori
ill
studi
also
note
increas
sensit
rp
assay
rel
molecular
test
target
rsv
parainfluenza
virus
influenza
b
advantag
filmarray
rp
includ
sampleinanswerout
format
largest
number
viral
respiratori
agent
current
market
rapid
result
minim
handson
time
perform
gener
compar
molecular
method
disadvantag
includ
limit
throughput
decreas
sensit
adenoviru
type
except
adenovirus
major
known
virus
caus
respiratori
tract
diseas
rna
virus
group
virus
whose
genom
gener
consid
exhibit
higher
rate
mutat
mutat
rate
rna
virus
influenza
extens
studi
exist
larg
sequenc
databas
virus
howev
import
respiratori
virus
rsv
parainfluenza
number
avail
sequenc
henc
knowledg
sequenc
variat
limit
group
undertak
project
sequenc
genom
import
agent
molecular
assay
reli
hybrid
primer
target
sequenc
detect
viru
lack
knowledg
full
extent
sequenc
variat
could
result
inabl
detect
particular
viral
strain
newli
aris
mutant
event
alreadi
occur
sweden
strain
chlamydia
trachomati
delet
mutat
render
nondetect
wide
use
commerci
molecular
assay
spread
around
countri
like
aid
product
falseneg
result
presum
goldstandard
diagnost
test
laboratori
switch
molecular
assay
detect
respiratori
agent
necessari
laboratorian
clinician
remain
vigil
case
appear
viral
respiratori
tract
infect
neg
molecular
result
formal
surveil
system
current
place
sentinel
laboratori
cultur
highthroughput
sequenc
capabl
would
one
solut
monitor
emerg
sequenc
variant
detect
standard
molecular
assay
avail
sequenc
data
rhinovirus
enterovirus
classifi
separ
genera
famili
picornavirida
sequenc
major
genom
group
reveal
close
relat
genera
combin
singl
genu
enteroviru
close
genom
similar
enterovirus
rhinovirus
made
difficult
design
pcr
assay
reliabl
discrimin
group
multiplex
assay
report
specimen
posit
rhinovirusenteroviru
situat
caus
confus
peopl
receiv
result
may
think
term
rhinovirus
classic
caus
commoncoldlik
infect
enterovirus
caus
asept
mening
system
ill
unpublish
data
author
laboratori
posit
rhinovirusenteroviru
multiplex
pcr
test
upper
lower
respiratori
tract
specimen
subject
sequenc
reveal
posit
rhinoviru
type
one
except
except
isol
enteroviru
enteroviru
type
known
caus
respiratori
tract
infect
furthermor
enteroviru
type
also
implic
caus
respiratori
tract
ill
therefor
case
rhinoviru
enteroviru
result
report
patient
suffer
viral
respiratorylik
ill
like
due
rhinoviru
enteroviru
capabl
caus
respiratori
tract
infect
although
presenc
asymptomat
shed
enteroviru
rule
virustest
laboratori
play
import
role
educ
health
care
worker
chang
picornaviru
taxonomi
interpret
result
report
posit
rhinovirusenteroviru
advent
molecular
test
assay
respiratori
viru
paradigm
consid
viral
agent
respiratori
diseas
alway
pathogen
detect
specimen
chang
numer
exampl
abil
detect
respiratori
viru
nucleic
acid
specimen
asymptomat
individu
primari
virus
detect
asymptomat
patient
rhinovirusesenterovirus
detect
normal
children
adult
well
immunocompromis
patient
virus
parainfluenza
virus
coronavirus
adenovirus
human
metapneumovirus
less
commonli
found
asymptomat
individu
studi
found
virus
rsv
influenza
metapneumoviru
rare
detect
asymptomat
individu
jansen
colleagu
specul
detect
viru
asymptomat
peopl
could
due
reason
detect
viru
acut
phase
infect
develop
symptom
detect
viru
still
shed
resolut
symptom
detect
viru
specimen
individu
experienc
subclin
infect
investig
also
quantifi
level
viral
nucleic
acid
specimen
found
gener
higher
level
viru
case
rel
asymptomat
control
howev
note
none
current
avail
fdaclear
assay
abil
quantifi
viru
specimen
addit
issu
standard
collect
method
respiratori
specimen
produc
meaning
quantit
result
detect
virus
asymptomat
person
concern
especi
rhinovirusenterovirus
detect
patient
caus
symptom
consid
case
coinfect
detect
see
next
section
suggest
laboratorian
familiar
issu
viral
detect
asymptomat
peopl
abl
provid
guidanc
health
care
worker
well
establish
multiplex
molecular
test
use
detect
respiratori
virus
specimen
contain
viru
coinfect
encount
frequenc
approxim
ascrib
signific
coinfect
respect
caus
sever
ill
complic
research
studi
differ
patient
popul
use
assay
capabl
detect
differ
set
virus
studi
found
certain
combin
virus
associ
sever
ill
wherea
other
report
infect
virus
may
interfer
infect
virus
beyond
scope
review
go
topic
depth
reader
refer
articl
paranhosbaccala
colleagu
detail
discuss
like
sever
method
patient
could
becom
infect
respiratori
viru
turn
could
affect
outcom
patient
unfortun
enough
becom
acut
infect
virus
time
depend
host
viru
es
outcom
could
sever
ill
hand
individu
previou
infect
viru
rhinoviru
still
asymptomat
shed
viru
becam
acut
superinfect
second
viru
scenario
like
would
produc
signific
ill
despit
fact
virus
would
detect
event
laboratori
institut
multiplex
molecular
test
respiratori
virus
expect
see
increas
incid
multipl
viral
infect
prepar
answer
question
clinician
use
test
past
sever
year
market
gone
virtual
fdaclear
molecular
assay
detect
respiratori
virus
wide
varieti
discuss
review
mention
addit
test
list
articl
number
test
avail
outsid
unit
state
within
unit
state
sold
researchuseonli
nonclear
format
test
describ
rang
kit
contain
primer
probe
detect
specif
group
virus
selfcontain
system
requir
special
instrument
extract
nucleic
acid
perform
pcr
littl
oper
input
test
target
virus
involv
larg
yearli
epidem
rsv
influenza
specif
group
virus
adenovirus
parainfluenza
virus
other
detect
known
respiratori
virus
well
bacteri
agent
system
util
plate
format
correspond
high
throughput
compar
other
much
limit
throughput
thing
repres
factor
taken
account
decid
use
one
assay
expect
clear
test
analyt
reach
market
futur
therebi
increas
competit
option
avail
also
like
see
complic
test
requir
train
technologist
replac
easytoperform
sampleinanswerout
format
test
test
simpl
may
grant
waiv
statu
therefor
found
provid
offic
pointofcar
situat
individu
microbiologist
infecti
diseas
physician
may
overse
use
bring
abil
rapidli
sensit
detect
respiratori
virus
place
previous
possibl
hope
simplif
molecular
test
caus
use
lose
sight
import
issu
associ
test
fals
neg
result
due
sequenc
variant
abil
detect
virus
individu
exhibit
symptom
signific
detect
coinfect
